关于完成变更独立董事的公告 证券代码：301089 证券简称：拓新药业 公告编号：2025-057 拓新药业集团股份有限公司 董事会 2025 年 11 月 13 日 附件： 董红杰女士简历： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开 第五届董事会第八次会议，审议通过《关于公司独立董事任期届满辞职暨补选独 立董事的议案》，具体内容详见公司于 2025 年 10 月 29 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于独立董事任期届满辞职暨补选独立董事的 公告》。 公司于 2025 年 11 月 13 日召开 2025 年第二次临时股东会，审议通过了《关 于公司独立董事任期届满辞职暨补选独立董事的议案》，同意选举董红杰女士、 杨德杰先生为公司第五届董事会独立董事（简历详见附件），任期自股东大会审 议通过之日起至第五届董事会任期届满时止。 近日，公司收到董红杰女士的通知，董红杰女士已按照相关规定参加了深圳 证券交易所举办的上市公司独立董事任前培训（线上 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-058 拓新药业集团股份有限公司 关于子公司拓新药业（内蒙古）有限公司 完成工商注册登记并取得营业执照的公告 名称：拓新药业（内蒙古）有限公司 统一社会信用代码：91150122MA0RU4T785 类型：有限责任公司(非自然人投资或控股的法人独资) 法定代表人：王秀强 注册资本：伍仟万元（人民币） 成立日期：2025 年 11 月 12 日 住所：内蒙古自治区呼和浩特市托克托县经济开发区管理委员会一楼 103 室 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开 第五届董事会第八次会议，审议通过了《关于对外投资设立子公司的议案》，同 意公司设立全资子公司拓新药业（内蒙古）有限公司，具体详见《关于对外投资 设立子公司拓新药业（内蒙古）有限公司的公告》（2025-055）。 近日，拓新药业（内蒙古）有限公司完成了工商注册登记手续，并取得了呼 和浩特托克托经济开发区管理委员会核发的《营业执照》，登记的具体信息如下： ...

一、会议召开和出席情况 证券代码：301089 证券简称：拓新药业 公告编号：2025-056 拓新药业集团股份有限公司 2025年第二次临时股东会决议公告 （一）会议召开时间： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 1.现场会议召开时间：2025年11月13日（星期四）上午9:00 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为2025 年11月13日（星期四）的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年11月13日 9:15-15:00期间的任意时间。 （二）会议召开地点：拓新药业集团股份有限公司会议室。 （三）会议召开方式：采取现场投票与网络投票相结合的方式。 （四）会议召集人：公司董事会 （五）会议主持人：董事长杨西宁先生 （六）本次股东会的召集、召开及表决方式符合《中华人民共和国公司法》 《上市公司股东会规则》《深圳证券交易所 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于拓新药业集团股份有限公司 2025 年第二次临时股东会的法律意见书 康达股会字【2025】第 0463 号 致：拓新药业集团股份有限公司 北京市康达律师事务所（以下简称"本所"）接受拓新药业集团股份有限公司（以 下简称"公司"）的委托，指派本所律师参加公司 2025 年第二次临时股东会（以下简 称"本次会议"）。 现本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公 司股东会规则》（以下简称"《股东会规则 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-059 拓新药业集团股份有限公司 关于子公司取得食品安全体系认证证书的公告 证书编号：162411011 有效期至：2027 年 11 月 12 日 认证标准：经 Intertek 现场审核，精泉生物符合 FSSC 22000 V6（食品制 造 ） 标 准 要 求 并 完 成 注 册 ， 该 认 证 体 系 涵 盖 ISO 22000:2018 ， ISO/TS 22002-1:2009 及 FSSC 22000 附加要求（V6） 适用范围：食品工业用一水肌酸、胞磷胆碱及叶酸的生产 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）全资子公司新乡精泉生物 技术有限公司（以下简称"精泉生物"）取得由国际知名认证公司 Intertek 签发 的《食品安全体系认证 FSSC 22000 证书》，现将相关事项公告如下： 一、证书内容： 证书名称：《食品安全体系认证 FSSC 22000 证书》 三、备查文件 1、《食品安全体系认证 FSSC 22000 证书》 ...

证券日报网讯拓新药业（301089）11月12日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司股东户数18538户。 ...

Core Points - The Shanghai Composite Index closed at 3993.35 points, remaining above the six-month moving average, with a slight decline of 0.24% [1] - The total trading volume of A-shares reached 1,270.245 billion yuan [1] - A total of 49 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Notable stocks with high deviation rates include: - Qudongli (驱动力) with a deviation rate of 5.91% and a daily increase of 7.05% [1] - Lubridge Information (路桥信息) with a deviation rate of 5.60% and a daily increase of 13.08% [1] - Beiyikang (倍益康) with a deviation rate of 4.75% and a daily increase of 7.60% [1] - Other stocks that just crossed the six-month moving average include: - Qianyuan Pharmaceutical (仟源医药) and *ST Jinke (*ST金科) with smaller deviation rates [1] Trading Activity - The trading turnover rate for Qudongli was 3.59%, while Lubridge Information had a turnover rate of 6.91% [1] - The stock with the highest turnover rate was Aipeng Medical (爱朋医疗) at 19.33% with a daily increase of 10.57% [1] Market Trends - The overall market shows a mix of stocks performing well above the six-month moving average, indicating potential bullish sentiment in certain sectors [1]

Core Viewpoint - The company has experienced a continuous decline in revenue and an increase in losses since its IPO, failing to leverage the capital market for growth, with current revenue levels even lower than pre-IPO figures [2][3]. Financial Performance - For the first three quarters, the company's revenue was 272 million yuan, a year-on-year decrease of 16.64%, with a loss of 30.16 million yuan, which has further expanded [2]. - In Q3 alone, revenue was 89.65 million yuan, down 16.21% year-on-year, marking the third consecutive quarter of revenue decline, and the net profit loss was 11.88 million yuan, continuing a six-quarter streak of losses [2]. - Historical performance shows a significant increase in revenue in the year following the IPO, but since then, revenue growth has slowed, with a projected near halving of revenue in 2024 compared to previous years [2][3]. Market Dynamics - The decline in performance is attributed to changes in market demand for antiviral raw materials, leading to a significant drop in sales, compounded by increased competition causing price declines and higher provisions for price reductions [2][3]. Strategic Investments - The company has increased its investment in new product development, resulting in higher R&D expenses, while new subsidiaries are in critical phases of product reserve and capacity ramp-up, leading to increased operational costs [3]. Stock Performance - The company's stock price peaked at 230 yuan per share post-IPO but has since fallen over 80%, with the latest closing price at 32.12 yuan per share [3]. - The stock experienced a cumulative decline of over 10% in 2022, followed by significant drops of 24.58% and 47.47% in 2023 and 2024, respectively, although there has been a slight increase in stock price this year [3]. Shareholder Activity - There have been over 60 recorded instances of share reductions by major shareholders and executives since the company went public, indicating a lack of confidence in the company's future [4]. - The controlling shareholder and actual controller have reduced their holdings by 312,210 shares, representing 2.47% of the total share capital [4]. - Notable shareholders have also reduced their stakes significantly, with some falling below 5% ownership, reflecting ongoing divestment trends [5].

Core Insights - TuoXin Pharmaceutical experienced a stock decline of 0.89% on November 6, with a trading volume of 59.96 million yuan [1] - The company reported a financing net buy of -1.90 million yuan on the same day, indicating more financing repayments than purchases [1] - As of November 6, the total financing and securities lending balance for TuoXin Pharmaceutical was 147 million yuan, representing 3.62% of its market capitalization [1] Financing Summary - On November 6, TuoXin Pharmaceutical had a financing buy amount of 4.42 million yuan, while the current financing balance stands at 147 million yuan, which is above the 50th percentile level over the past year [1] - The company repaid 700 shares of securities lending and sold 200 shares on the same day, with a selling amount of 6,424 yuan [1] - The securities lending balance is 122,100 yuan, which is below the 20th percentile level over the past year, indicating a low position [1] Business Performance - As of October 31, TuoXin Pharmaceutical had 18,700 shareholders, an increase of 3.48% from the previous period, with an average of 4,839 circulating shares per shareholder, a decrease of 3.36% [2] - For the period from January to September 2025, the company reported a revenue of 272 million yuan, a year-on-year decrease of 16.64%, and a net profit attributable to the parent company of -30.16 million yuan, a significant decrease of 1,036.53% [2] - Since its A-share listing, TuoXin Pharmaceutical has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2] Company Overview - TuoXin Pharmaceutical Group Co., Ltd. is located in Xinxiang City, Henan Province, and was established on February 3, 2005, with its listing date on October 27, 2021 [1] - The company's main business involves the research, production, and sales of chemical synthesis and biological fermentation nucleoside (acid) raw materials and pharmaceutical intermediates [1] - The revenue composition of the company includes 62.74% from pharmaceutical intermediates, 37.03% from raw materials, and 0.23% from other sources [1]

Core Viewpoint - The company, Tuoxin Pharmaceutical, confirmed that it is not currently subject to delisting risk warnings or other risk warnings, emphasizing its commitment to improving operational management and profitability for long-term stable development [1] Group 1 - The company responded to investor inquiries on November 3, indicating compliance with relevant regulations [1] - Tuoxin Pharmaceutical aims to enhance its governance and profitability [1] - The company is focused on promoting long-term stability and development [1]